Switch theme
Sign up to access all valuation multiples
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
1939
16.2K+
LTM Revenue $13.2B
LTM EBITDA $2.5B
$21.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Astellas Pharma has a last 12-month revenue (LTM) of $13.2B and a last 12-month EBITDA of $2.5B.
In the most recent fiscal year, Astellas Pharma achieved revenue of $11.0B and an EBITDA of $1.3B.
Astellas Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Astellas Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.2B | XXX | $11.0B | XXX | XXX | XXX |
| Gross Profit | $10.7B | XXX | $9.0B | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $2.5B | XXX | $1.3B | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $464M | XXX | $130M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 1% | XXX | XXX | XXX |
| Net Profit | $453M | XXX | $117M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Astellas Pharma's stock price is JPY 1429 (or $10).
Astellas Pharma has current market cap of JPY 2.56T (or $17.6B), and EV of JPY 3.17T (or $21.8B).
See Astellas Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21.8B | $17.6B | XXX | XXX | XXX | XXX | $0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Astellas Pharma has market cap of $17.6B and EV of $21.8B.
Astellas Pharma's trades at 2.0x EV/Revenue multiple, and 15.3x EV/EBITDA.
Equity research analysts estimate Astellas Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Astellas Pharma has a P/E ratio of 38.7x.
See valuation multiples for Astellas Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.6B | XXX | $17.6B | XXX | XXX | XXX |
| EV (current) | $21.8B | XXX | $21.8B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 15.3x | XXX | XXX | XXX |
| EV/EBIT | 46.9x | XXX | 67.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 38.7x | XXX | 68.3x | XXX | XXX | XXX |
| EV/FCF | 19.8x | XXX | 24.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAstellas Pharma's last 12 month revenue growth is 2%
Astellas Pharma's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.5M for the same period.
Astellas Pharma's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Astellas Pharma's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Astellas Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 53% | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Astellas Pharma acquired XXX companies to date.
Last acquisition by Astellas Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Astellas Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Astellas Pharma founded? | Astellas Pharma was founded in 1939. |
| Where is Astellas Pharma headquartered? | Astellas Pharma is headquartered in Japan. |
| How many employees does Astellas Pharma have? | As of today, Astellas Pharma has 16.2K+ employees. |
| Who is the CEO of Astellas Pharma? | Astellas Pharma's CEO is Mr. Naoki Okamura. |
| Is Astellas Pharma publicy listed? | Yes, Astellas Pharma is a public company listed on TKS. |
| What is the stock symbol of Astellas Pharma? | Astellas Pharma trades under 4503 ticker. |
| When did Astellas Pharma go public? | Astellas Pharma went public in 1949. |
| Who are competitors of Astellas Pharma? | Similar companies to Astellas Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Astellas Pharma? | Astellas Pharma's current market cap is $17.6B |
| What is the current revenue of Astellas Pharma? | Astellas Pharma's last 12 months revenue is $13.2B. |
| What is the current revenue growth of Astellas Pharma? | Astellas Pharma revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Astellas Pharma? | Current revenue multiple of Astellas Pharma is 1.7x. |
| Is Astellas Pharma profitable? | Yes, Astellas Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Astellas Pharma? | Astellas Pharma's last 12 months EBITDA is $2.5B. |
| What is Astellas Pharma's EBITDA margin? | Astellas Pharma's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Astellas Pharma? | Current EBITDA multiple of Astellas Pharma is 8.6x. |
| What is the current FCF of Astellas Pharma? | Astellas Pharma's last 12 months FCF is $1.1B. |
| What is Astellas Pharma's FCF margin? | Astellas Pharma's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Astellas Pharma? | Current FCF multiple of Astellas Pharma is 19.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
